



Editor's choice
Scan to access more
free content

ORIGINAL ARTICLE

Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry

Joan Sweeney,¹ Chris C Patterson,² Andrew Menzies-Gow,³ Rob M Niven,⁴ Adel H Mansur,⁵ Christine Bucknall,⁶ Rekha Chaudhuri,⁷ David Price,⁸ Chris E Brightling,⁹ Liam G Heaney,¹ on behalf of the British Thoracic Society Difficult Asthma Network

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/thoraxjnl-2015-207630>).

For numbered affiliations see end of article.

Correspondence to

Professor Liam G Heaney, Centre for Infection and Immunity, Queen's University of Belfast, Wellcome-Wolfson Institute for Experimental Medicine, 97 Lisburn Road, Belfast BT9 7BL, UK; jsweeney13@qub.ac.uk

Received 3 August 2015

Revised 16 December 2015

Accepted 28 December 2015

Published Online First

27 January 2016



► <http://dx.doi.org/10.1136/thoraxjnl-2015-208242>



CrossMark

To cite: Sweeney J, Patterson CC, Menzies-Gow A, et al. *Thorax* 2016;**71**:339–346.

ABSTRACT

Objective To determine the prevalence of systemic corticosteroid-induced morbidity in severe asthma.

Design Cross-sectional observational study.

Setting The primary care Optimum Patient Care Research Database and the British Thoracic Society Difficult Asthma Registry.

Participants Optimum Patient Care Research Database (7195 subjects in three age- and gender-matched groups)—severe asthma (Global Initiative for Asthma (GINA) treatment step 5 with four or more prescriptions/year of oral corticosteroids, n=808), mild/moderate asthma (GINA treatment step 2/3, n=3975) and non-asthma controls (n=2412). 770 subjects with severe asthma from the British Thoracic Society Difficult Asthma Registry (442 receiving daily oral corticosteroids to maintain disease control).

Main outcome measures Prevalence rates of morbidities associated with systemic steroid exposure were evaluated and reported separately for each group. **Results** 748/808 (93%) subjects with severe asthma had one or more condition linked to systemic corticosteroid exposure (mild/moderate asthma 3109/3975 (78%), non-asthma controls 1548/2412 (64%); p<0.001 for severe asthma versus non-asthma controls). Compared with mild/moderate asthma, morbidity rates for severe asthma were significantly higher for conditions associated with systemic steroid exposure (type II diabetes 10% vs 7%, OR=1.46 (95% CI 1.11 to 1.91), p<0.01; osteoporosis 16% vs 4%, OR=5.23, (95% CI 3.97 to 6.89), p<0.001; dyspeptic disorders (including gastric/duodenal ulceration) 65% vs 34%, OR=3.99, (95% CI 3.37 to 4.72), p<0.001; cataracts 9% vs 5%, OR=1.89, (95% CI 1.39 to 2.56), p<0.001). In the British Thoracic Society Difficult Asthma Registry similar prevalence rates were found, although, additionally, high rates of osteopenia (35%) and obstructive sleep apnoea (11%) were identified.

Conclusions Oral corticosteroid-related adverse events are common in severe asthma. New treatments which reduce exposure to oral corticosteroids may reduce the prevalence of these conditions and this should be considered in cost-effectiveness analyses of these new treatments.

Key messages

What is the key question?

- What is the prevalence of systemic corticosteroid-induced morbidity in severe asthma?

What is the bottom line?

- This study provides for the first time, prevalence data for common systemic corticosteroid adverse effects in severe asthma, including type II diabetes, osteopenia/osteoporosis, dyspeptic disorders, obesity, hypertension, cataracts and obstructive sleep apnoea.

Why read on?

- These prevalence data will be helpful in cost-effectiveness analyses for new biological treatments with corticosteroid-sparing activity in severe asthma and in identifying the need for systematic screening programmes in severe asthma.

INTRODUCTION

Patients with severe asthma (SA) pose a significant challenge to healthcare professionals. Despite treatment with high-dose inhaled corticosteroids plus a second controller and/or systemic corticosteroid therapy, most still have poor asthma control, persistent airflow limitation and frequent severe exacerbations.¹ Evidence shows that adverse effects occur in various populations with respiratory disease and other non-respiratory conditions receiving frequent oral corticosteroids (OCS).^{2–15} Many of the studies of respiratory disease included small numbers, were in mixed-disease populations, did not have control groups or relied on commercial healthcare reimbursement claims data or patient self-reporting of symptoms or morbidity, but few prevalence data are available in a well-

characterised cohort with SA. It is important to define the prevalence of systemic corticosteroid-induced morbidity in this specific population to understand the consequences of progression to maintenance OCS and thus to determine the potential benefit of new steroid-sparing treatments in SA. Prevalence data are also key to informing cost-effectiveness analyses for these new asthma treatments with specific corticosteroid-sparing strategies

Common corticosteroid adverse effects range from psychological effects such as irritability, sleep disturbance and increased appetite to severe and potentially life-threatening conditions such as diabetes, cardiovascular disorders and adrenal suppression.^{2–6} These major adverse effects are a substantial healthcare and economic burden and have a major detrimental effect on patients and their families and carers. However, even minor effects, although having a negligible economic burden, may have a significant impact on patients' quality of life, with associated physical and psychosocial impairment. All these effects will affect patients' willingness to adhere to treatment.

The aim of this study was to provide precise prevalence data of adverse events associated with systemic steroid exposure in well-characterised SA.

METHODS

Data from the Optimum Patient Care Research Database (OPCRD)¹⁶ and British Thoracic Society (BTS) Difficult Asthma Registry¹⁷ (both described in the online supplementary data) were used to identify the cross-sectional prevalence of conditions due to systemic corticosteroid exposure in patients with SA. The most commonly reported adverse effects of OCS use are listed in online supplementary table E1 and the data were examined for these outcomes.^{2–15}

The OPCRD is a UK respiratory database containing anonymised primary care data supplemented with information from patient-reported questionnaires. The BTS Registry collects data from UK dedicated Specialist Difficult Asthma Services and is hosted online by Dendrite Clinical Systems and admits password-protected anonymised data, after fully informed written consent.

SUBJECTS

Optimum Patient Care Research Database

We compared patients with SA requiring regular OCS (defined as Global Initiative for Asthma (GINA) step 5 treatment and four or more prescriptions for OCS in each of two consecutive study years) with patients with mild/moderate asthma and non-asthmatic controls. Subjects had at least 2 years of continuous medical records and were aged >12 years. We identified two control cohorts, individually matched to the SA cohort for age, gender and year of birth, one with mild/moderate asthma (asthma diagnosis, GINA step 2/3), the other consisting of non-asthmatic controls (rhinitis diagnosis with no asthma diagnosis/asthma drugs and no exposure to OCS). Full details of cohort definition are available in the online supplementary data. A subgroup of subjects with SA who received maintenance systemic corticosteroids, quantified by six or more OCS prescriptions in both years of the study, was further evaluated (see online supplementary data and table E3 for results).

BTS Registry

We performed an additional analysis of prevalence rates of conditions associated with systemic steroid exposure in subjects with SA who had detailed follow-up data in the BTS Registry for at least 1 year (n=770). Two groups were defined—group 1—subjects, who after detailed systematic assessment required daily systemic corticosteroid therapy to maintain asthma control (n=442, severe OCS-dependent asthma (CSD)) and group 2, subjects with SA who did not require maintenance OCS but required frequent rescue courses of corticosteroids (n=328, severe non-corticosteroid-dependent asthma (NCSD)).

Data analysis

Statistical analysis was performed using SPSS for Windows V.19. Demographic data are presented as absolute values (%), mean \pm SD if normally distributed or median and IQR where not normally distributed. Group differences were examined using the two-sample t test, Mann–Whitney U test or χ^2 test, as appropriate.

Disease prevalence estimates are presented as both absolute numbers and percentages with 95% CIs. Existing morbidities

Table 1 Demographic details of the OPCRD cohorts (for list of steroid-induced morbidities see online supplementary table E1)

Demographics	All (n=7195)	Severe asthma (n=808)	Mild/moderate asthma (n=3975)	Non-asthma controls (n=2412)	p Value
Female, n (%)	4503 (63)	507 (63)	2515 (63)	1481 (61)	–
Age (years)*	58 \pm 17	59 \pm 17	58 \pm 16	58 \pm 17	–
Geographical region, n (%)					0.06
London	597 (8)	55 (7)	344 (9)	198 (8)	
South of England	903 (13)	93 (12)	477 (12)	333 (14)	
East of England	1064 (15)	115 (14)	616 (15)	333 (14)	
Midlands	2146 (30)	248 (31)	1213 (31)	685 (28)	
North of England	1648 (23)	193 (24)	874 (22)	581 (24)	
Scotland/NI/Wales/unknown	837 (12)	104 (13)	451 (11)	282 (12)	
Number of corticosteroid-related comorbidities† n (%)					<0.001
0	1790 (25)	60 (7)	866 (22)	864 (36)	
1	1754 (24)	136 (17)	1044 (26)	574 (24)	
2	1382 (19)	181 (22)	797 (20)	404 (17)	
\geq 3	2269 (32)	431 (53)	1268 (32)	570 (24)	

p Values are not provided for age/gender as cohorts were matched based on age/gender.

*Mean \pm SD.

†See online supplementary table E1 for morbidities examined.

OPCRD, Optimum Patient Care Research Database.

recorded at any time in the data were evaluated and reported separately for each group. In the OPCRD, the proportions of subjects with SA, mild/moderate asthma and non-asthma controls with OCS morbidity were obtained using cross-tabulations. Conditional logistic regression analysis was then used to estimate the OR, 95% CIs and *p* values for the SA cohort relative to each control group taking account of the matched nature of the cohorts. In the BTS Registry, OR and 95% CIs were obtained from logistic regression analysis, adjusting for potential confounding variables such as hospital, age and gender. A *p* value of <0.05 was considered statistically significant.

RESULTS

Optimum Patient Care Research Database

Demographics of all subjects are presented in [table 1](#).

In subjects with SA, there was a predominance of women (63%) with a mean age of 59 (± 17) years. Potential corticosteroid-induced morbidities were identified in 93% of subjects with SA and 53% had three or more morbidities, which was significantly higher than for both mild/moderate asthma and non-asthmatic controls ([table 1](#) and online supplementary [table E1](#), $p < 0.001$).

For subjects where complete and detailed prescribing records were available for the 2 study years ($n = 470$), the median daily dose of prednisolone in SA was 5 mg (IQR 3–9 mg) and 0 mg (0–1 mg) in mild/moderate asthma, with zero OCS exposure in the non-asthma control cohort. Similarly, the cumulative OCS dose over the 2 study years was median 3920 mg (IQR 2395–6500 mg) in SA and 250 mg (150–420 mg) in mild/moderate asthma.

[Table 2](#) describes the observed prevalence rates of the comorbidities examined across SA, mild/moderate asthma and non-asthma controls. The most prevalent comorbidities identified in subjects with SA were dyspeptic disorders (65%), obesity (42%), psychiatric disorders (38%), hypertension (34%), osteoporosis (16%), hypercholesterolaemia (15%), chronic kidney disease (14%), type II diabetes (10%), osteopenia (10%) and cardiovascular disease (10%).

With the exception of glaucoma and hypercholesterolaemia, subjects with SA had a significantly higher risk ($OR > 1$) of all other adverse effects previously linked to OCS exposure than subjects with mild/moderate asthma. The odds of having type II diabetes, cataracts, sleep disorders, fractures and chronic kidney disease was 1.5–2 times higher for subjects with SA than for those with mild/moderate asthma. The odds of dyspeptic disorder was almost four times higher in SA while the odds of having osteopenia or osteoporosis in SA was over five times higher in SA than in mild/moderate asthma.

Comparison of patients with SA with non-asthma controls showed that all morbidities examined were significantly more prevalent in SA, with the exception of glaucoma. The odds of having type II diabetes, cardiovascular disease, hypertension, psychiatric disorders and fractures was 1.5–2 times higher in SA than in non-asthma controls. The odds of obesity (body mass index $> 30 \text{ kg/m}^2$) in SA were doubled compared with non-asthma controls. The odds of dyspeptic disorders were almost five times higher while sleep disorders, cataracts and chronic kidney disease were over twice as likely in subjects with SA. The odds of osteoporosis or osteopenia in SA was almost seven times that of the non-asthma controls.

BTS Registry

Demographic details and clinical data of the BTS Registry cohorts are available in [table 3](#). It is important to emphasise that the comparator NCSD cohort, although not receiving

maintenance OCS, had significant rescue systemic corticosteroid exposure despite high-dose inhaled corticosteroids, consistent with SA (median IQR rescue OCS prescriptions 4 (2–6) in the 12 months before referral). The primary purpose of this analysis was to understand the consequences of progression to daily maintenance OCS compared with frequent rescue steroids.

Again, subjects overall with SA were more likely to be female but there was a greater proportion in the NCSD cohort. Baseline body mass index was significantly lower in the NCSD cohort than in the CSD cohort. The NCSD cohort was more likely to be in full time employment, with significantly fewer not working owing to their asthma. Subjects in the non-corticosteroid cohort were more likely to be current smokers.

Pre-bronchodilator FEV₁ was significantly higher and less obstructive in the non-corticosteroid cohort ($77.42 \pm 25.09\%$ predicted vs $66.70 \pm 24.05\%$ predicted, $p < 0.001$). For health-care use at baseline, subjects in the severe NCSD cohort had significantly fewer unscheduled visits to their general practitioner or to Accident and Emergency ($p = 0.035$) and hospital admissions in the previous 12 months ($p < 0.001$). Previous admission to the intensive therapy unit (ITU) was also lower ($p < 0.001$), although overall ITU admission rates were low in both cohorts.

Despite not receiving maintenance OCS, the NCSD cohort were exposed to frequent rescue courses of OCS (median 4 (IQR 1–6)), although pre-referral rescue OCS courses were significantly higher in the CSD cohort (median 5 (IQR 2–8)), as was the inhaled corticosteroid dose (2000 (1600–2000) vs 2000 (1000–2000) μg beclomethasone dipropionate equivalent) and daily short-acting β -agonist use (median 8 (4–10) vs 6 (4–10)).

Hospital Anxiety and Depression Scale (HADS, $n = 510$), Asthma Quality of Life Questionnaire (AQLQ, $n = 434$) and EuroQoL (EQ-5D, $n = 414$) data were available to assess anxiety/depression, asthma and generic-related quality of life scores. Mean anxiety scores were > 8 , suggestive of mild anxiety in both cohorts but, additionally, depression scores for subjects with severe corticosteroid-dependent asthma were significantly higher than in those with non-corticosteroid asthma ($p = 0.001$), although remained in the normal range.

Quality-of-life scores were significantly lower for subjects in the CSD cohort for both EQ-5D domain and Visual Analogue Scale scores. AQLQ scores were also significantly higher for subjects not receiving maintenance OCS across all domains (see [table 3](#)).

Potential corticosteroid-induced morbidities were more commonly seen in subjects receiving maintenance OCS than in subjects with NCSD, with 20% of subjects with NCSD asthma having three or more comorbidities compared with 53% of subjects with CSD asthma ([table 3](#) and online supplementary [table E1](#), $p < 0.001$).

Prevalence of corticosteroid-induced morbidity in subjects with NCSD in the BTS Registry

The prevalence rates of the major adverse effects examined (see online supplementary [table E1](#)) were significantly lower in the NCSD cohort with the exception of osteoporosis, osteopenia, cardiovascular disease and glaucoma ([table 4](#)). However, high rates of obesity (45%), psychiatric disorders (14%), dyspeptic symptoms (48%) and hypertension (15%) were still apparent in the NCSD cohort. After controlling for age, hospital and gender, associations with severe CSD asthma were strongest for type II diabetes and obstructive sleep apnoea.

Eighty-nine percent of those with NCSD asthma with a report of psychiatric disorder had completed HADS at baseline compared with 69% of those with corticosteroid-dependent

Table 2 Prevalence rates of potential systemic corticosteroid-induced comorbidity and comparisons by groups in the OPCRD dataset

Morbidity	Severe asthma (%) (n=808)	Mild/moderate asthma (%) (n=3975)	OR (95% CI)*	p Value*	Non-asthma controls (%) (n=2412)	OR (95% CI)*	p Value*
Type II diabetes	82 (10)	281 (7)	1.46 (1.11 to 1.91)	0.006	149 (6)	1.76 (1.30 to 2.38)	<0.001
Obesity (BMI >30 kg/m ²)	339 (42)	1385 (35)	1.36 (1.16 to 1.59)	<0.001	561 (23)	2.04 (1.74 to 2.39)	<0.001
Osteopenia	78 (10)	85 (2)	5.26 (3.75 to 7.37)	<0.001	41 (2)	6.68 (4.28 to 10.43)	<0.001
Osteoporosis	126 (16)	162 (4)	5.23 (3.97 to 6.89)	<0.001	74 (3)	6.53 (4.63 to 9.21)	<0.001
Fracture	41 (5)	134 (3)	1.54 (1.06 to 2.22)	0.022	88 (4)	1.65 (1.14 to 2.39)	0.007
Dyspeptic disorders	524 (65)	1331 (34)	3.99 (3.37 to 4.72)	<0.001	578 (24)	4.88 (4.11 to 5.79)	<0.001
Glaucoma	32 (4)	137 (3)	1.12 (0.75 to 1.68)	0.58	67 (3)	1.41 (0.89 to 2.25)	0.15
Cataract	70 (9)	195 (5)	1.89 (1.39 to 2.56)	<0.001	105 (4)	2.42 (1.70 to 3.43)	<0.001
Cardiovascular disease	77 (10)	277 (7)	1.36 (1.02 to 1.81)	0.035	168 (7)	1.57 (1.14 to 2.15)	0.005
Hypertension	276 (34)	1145 (29)	1.35 (1.12 to 1.61)	0.001	596 (25)	1.76 (1.44 to 2.14)	<0.001
Psychiatric conditions/anxiety/depression	310 (38)	1238 (31)	1.43 (1.22 to 1.69)	<0.001	607 (25)	1.67 (1.42 to 1.97)	<0.001
Hypercholesterolaemia	124 (15)	561 (14)	1.15 (0.92 to 1.44)	0.21	258 (11)	1.61 (1.25 to 2.08)	<0.001
Sleep disorder	33 (4)	99 (2.5)	1.70 (1.13 to 2.53)	0.010	40 (2)	2.21 (1.46 to 3.35)	<0.001
Chronic kidney disease	110 (14)	342 (9)	1.80 (1.39 to 2.32)	<0.001	167 (7)	2.41 (1.81 to 3.21)	<0.001

*OR (95% CI) and p values are calculated for the severe asthma cohort relative to each of the other two groups. BMI, body mass index; OPCRD, Optimum Patient Care Research Database.

asthma. Clinically significant anxiety symptoms were confirmed by a HADS-A score ≥ 11 and were present in the NCS cohort (11.54 ± 5.44) while in the corticosteroid-dependent cohort anxiety scores were above normal ranges (10.69 ± 4.27), although this difference failed to reach statistical significance ($p=0.38$). HADS depression scores were also higher in those with NCS asthma and were suggestive of depression in both cohorts and supportive of the diagnosis (9.29 ± 5.13 vs 8.84 ± 3.71 , $p=0.61$), but the difference was not statistically significant.

Prevalence rates for corticosteroid-induced morbidity in OPCRD compared with the BTS Registry

The selection criteria for SA from OPCRD (GINA step 5 treatment and four or more prescriptions for OCS in each of two consecutive study years) would apply to the majority of subjects in the BTS Registry and we therefore compared morbidity prevalence rates from both datasets (table 5). (Formal statistical comparison of prevalence rates between the OPCRD and the BTS Registry was not thought to be appropriate because of the differing ascertainment methods used in the two sources.)

DISCUSSION

Treatment with systemic corticosteroids in some patients with SA helps to improve asthma control and reduce exacerbation rates through their anti-inflammatory effects. However, data from the OPCRD and the BTS Difficult Asthma Registry shows that patients with SA have substantial excess morbidity from multiple diseases and adverse effects associated with systemic corticosteroid exposure. Differences are apparent when comparing prevalence rates in subjects with SA who are NCS but require frequent rescue courses of OCS each year and compared with subjects with mild/moderate asthma and non-asthma controls. To our knowledge, these are the first data reporting prevalence rates of potential systemic corticosteroid-induced comorbidity specifically in subjects with SA.

Most subjects (92–93%) with SA examined had at least one condition which has been linked to systemic corticosteroid exposure, with significantly higher prevalence rates than in subjects with mild/moderate asthma, and higher again than in subjects examined

without asthma. Several studies have investigated comorbidity in patients with asthma compared with non-asthmatic controls but in those studies it is difficult to differentiate asthma severity or systemic corticosteroid exposure and any potential influence on the development of comorbid disease.^{18–23} Steppuhn *et al*¹⁸ showed that 60% of subjects with asthma in their study reported at least one comorbidity, with 18% reporting at least three comorbidities; similar rates were found in a younger asthmatic population by Karlstad *et al*.²² Our data showed that subjects with mild/moderate asthma (GINA step 2/3 treatment) who are matched for age and gender have a prevalence of comorbidity similar to that of non-asthmatic controls, suggesting that much of the additional comorbidity associated with asthma is due to systemic corticosteroid exposure.

Several systematic reviews in multiple heterogeneous and different patient groups have shown that systemic corticosteroids are a common cause of adverse events in patients exposed to regular doses of OCS.^{3 4 24} Among the most frequently reported morbidities were osteoporosis, dyspeptic disorders, sleep disturbance, hypertension, diabetes, fractures and cataracts, which is similar to our data in SA. Zazzali *et al*¹⁵ demonstrated in a mixed respiratory cohort that the most common adverse effects of OCS use were hypertension, lipid disorders and diabetes. These new data from OPCRD and the BTS Registry have identified strong associations with many of these conditions and others which are associated with the use of OCS in SA.

Data from two different datasets in SA shows that the estimated prevalence for the majority of the corticosteroid-induced morbidities is similar and we believe these estimates are reflective of the prevalence of these conditions in this population. These disease estimates will inform cost analyses in this group to better capture the true effects of regular systemic corticosteroid exposure. Some differences were noted when comparing the OPCRD data with that from the BTS Registry. Higher rates of osteopenia and obstructive sleep apnoea were found in the BTS Registry subjects compared with subjects with SA in the OPCRD and a number of factors may explain these differences. First, subjects from the BTS Registry were receiving substantially higher doses of inhaled corticosteroids than the OPCRD SA

Table 3 Demographic details, medication, healthcare use and quality-of-life scores British Thoracic Society Severe Asthma Registry at time of initial clinical assessment

	All (n=770)	Severe non-corticosteroid-dependent asthma (n=328)	Severe corticosteroid-dependent asthma (n=442)	p Value
Female (%)	502 (65)	233 (71)	269 (61)	0.003
Age in September 2013	50±14.5	48.4±15.47	50.5±13.7	0.05
Caucasian (%)	694 (90)	290 (88)	404 (91)	0.17
Age (years) asthma diagnosed	16 (4–35)	13 (4–35)	18 (4–35)	0.38
BMI (kg/m ²)	30.3±6.9	29.5±7.1	30.9±6.7	0.009
Smoking status				
Current (%)	61 (8)	36 (11)	25 (6)	0.007
Ex-smoker (%)	210 (27)	84 (26)	126 (29)	0.37
Employment status				
Full-time employment (%)	307 (40)	157 (48)	150 (34)	<0.001
Not working due to asthma (%)	198 (26)	53 (16)	145 (33)	<0.001
FEV ₁ (% predicted)	71.27±25.05	77.42±25.09	66.70±24.05	<0.001
FEV ₁ /FVC ratio (%)	65.22±14.96	67.91±14.49	63.16±15.01	<0.001
Median unscheduled visits to GP or A&E in preceding 12 months (IQR)	4 (2–6)	4 (1–6)	4 (2–7)	0.035
Median total number of ITU admissions ever (IQR)	0 (0–0)	0 (0–0)	0 (0–1)	<0.001
Median hospital admissions in previous 12 months (IQR)	0 (0–2)	0 (0–1)	1 (0–2)	<0.001
Median rescue OCS courses in preceding 12 months (IQR)	4 (2–6)	4 (1–6)	5 (2–8)	<0.001
Median prednisolone dose (IQR) (mg)	–	–	15 (10–20)	–
Median BDP equivalent dose (IQR) (µg)	2000 (1200–2000)	2000 (1000–2000)	2000 (1600–2000)	<0.001
Median SABA use (IQR) (puffs per day)	8 (4–10)	6 (4–10)	8 (4–10)	0.002
HADS anxiety	8.41±4.82	8.18±4.95	8.61±4.72	0.32
HADS depression	6.55±4.37	5.83±4.41	7.15±4.26	0.001
EQ-5D	0.58±0.34	0.63±0.33	0.53±0.33	0.002
EQ-VAS	55±21.5	58±21.9	53±20.9	0.013
AQLQ symptom score	3.36±1.45	3.72±1.34	3.07±1.47	p<0.001
AQLQ activity score	3.66±1.30	3.96±1.35	3.41±1.22	<0.001
AQLQ emotional score	3.32±1.58	3.74±1.61	2.98±1.48	<0.001
AQLQ environment score	3.97±1.57	4.2±1.52	3.79±1.58	0.005
AQLQ total score	3.54±1.24	3.86±1.26	3.30±1.18	<0.001
Number of corticosteroid-induced morbidities (%) (online supplementary table E1)				
0	118 (15)	82 (25)	36 (8)	<0.001
1	182 (24)	105 (32)	77 (17)	
2	171 (22)	75 (23)	96 (22)	
≥3	299 (39)	66 (20)	233 (53)	

Data are shown as mean±SD unless otherwise specified.

A&E, Accident and Emergency; AQLQ, Asthma Quality of Life Questionnaire; BDP, beclomethasone dipropionate; BMI, body mass index; EQ, EuroQoL; GP, general practitioner; HADS, Hospital Anxiety and Depression Scale; ITU, intensive therapy unit; OCS, oral corticosteroids; SABA, short-acting β agonist; VAS, Visual Analogue Scale.

cohort. Second, subjects in the BTS Registry all had detailed systematic assessment in specialist centres, where problems such as adherence to treatment and screening for assessment of corticosteroid-induced comorbidities with routine dual energy X ray absorptiometry scanning and assessment for obstructive sleep apnoea is routine.^{1 25 26} Higher rates of psychiatric disorders, hypertension, cardiovascular disease, glaucoma, cataracts and fractures were evident in subjects with SA in the OPCRd than in the BTS Registry. The advantage of using a primary care database is that recording of such conditions is completed routinely in line with the Quality and Outcomes Framework (QOF) where general practitioners are reimbursed for maintaining disease registers and reviewing patients with certain conditions. Interestingly four out of six of the aforementioned conditions are included in this QOF. It is also possible that these conditions are under-reported in the Registry. It is important that these differences are considered in the future provision of detailed screening programmes for patients with SA exposed to regular systemic corticosteroids.

A new finding of this study is the association with SA and chronic kidney disease, although this is perhaps not surprising considering the high prevalence rates of overlapping major risk factors, including diabetes, hypertension and obesity. This study supports the importance of inclusion of early and regular assessment and prevention measures as part of the systematic management of these patients in order to avoid progression to dialysis and risk of other costly consequences such as cardiovascular disease and premature death.

Using data from the BTS Registry we have been able to demonstrate that regular daily corticosteroid exposure is associated with a measurably greater prevalence of corticosteroid-associated morbidities compared with subjects with severe disease receiving frequent rescue courses. We were also able to demonstrate significantly lower asthma and generic quality-of-life scores in asthma requiring maintenance corticosteroids and taken together, this suggests that the move to daily corticosteroids, while potentially providing better asthma control and reduced exacerbation risk, is likely to have a major

Table 4 Prevalence rates of corticosteroid-induced morbidity and comparisons between cohorts in the BTS Registry

Disease/adverse event	Severe corticosteroid-dependent asthma (442) n (%)	Severe non-corticosteroid-dependent asthma (328) n (%)	OR (95% CI)*	OR (95% CI)†	OR (95% CI)‡	p Value
Endocrine disorder						
IDDM	2 (0.5)	1 (0.3)	–	–	–	1.00
NIDDM	64 (14)	15 (5)	3.55 (1.98 to 6.35)	3.50 (1.94 to 6.24)	3.48 (1.94 to 6.26)	<0.001
Cardiac disease						
Hypertension	98 (22)	49 (15)	1.61 (1.11 to 2.36)	1.59 (1.07 to 2.36)	1.59 (1.07 to 2.37)	0.012
Cardiovascular disease	27 (6)	25 (8)	0.78 (0.44 to 1.37)	0.74 (0.41 to 1.33)	0.71 (0.39 to 1.30)	0.41
Hypercholesterolaemia	76 (17)	24 (7)	2.61 (1.60 to 4.23)	2.64 (1.60 to 4.37)	2.59 (1.57 to 4.30)	<0.001
Osteoporosis and bone disease						
Osteoporosis	57/319 (18)	18/122 (15)	1.26 (0.71 to 2.24)	1.27 (0.71 to 2.28)	1.21 (0.67 to 2.17)	0.44
Osteopenia	117/319 (37)	39/122 (32)	1.22 (0.78 to 1.90)	1.23 (0.79 to 1.92)	1.15 (0.73 to 1.81)	0.36
Fracture	13 (3)	1 (0.3)	–	–	–	0.007
Obesity (BMI > 30 kg/m ²)	237 (54)	147 (45)	1.43 (1.07 to 1.91)	1.41 (1.06 to 1.88)	1.47 (1.10 to 1.97)	0.016
Weight gain	55 (12)	3 (1)	–	–	–	<0.001
Sleep disorders						
Sleep disturbance	18 (4)	2 (1)	–	–	–	0.003
Obstructive sleep apnoea	51 (12)	13 (4)	3.14 (1.68 to 5.89)	3.07 (1.64 to 5.77)	2.80 (1.48 to 5.29)	<0.001
Eye disease						
Cataracts	25 (6)	0 (0)	–	–	–	0.002
Glaucoma	8 (2)	6 (2)	0.97 (0.33 to 2.83)	0.93 (0.31 to 2.74)	0.83 (0.28 to 2.50)	0.98
Dyspeptic disorders	283 (64)	157 (48)	2.00 (1.49 to 2.68)	1.94 (1.44 to 2.61)	1.96 (1.45 to 2.64)	<0.001
Psychiatric disorders						
Depression/anxiety/low mood	125 (28)	46 (14)	2.36 (1.62 to 3.44)	2.39 (1.64 to 3.49)	2.57 (1.76 to 3.76)	<0.001
Skin conditions	16 (4)	1 (0.3)	–	–	–	0.002
Corticosteroid-related diseases						
Cushingoid symptoms	27 (6)	1 (0.3)	–	–	–	<0.001
Adrenal insufficiency	12 (3)	1 (0.3)	–	–	–	0.010
Corticosteroid-induced proximal myopathy	1 (0.2)	0	–	–	–	1.00

*OR adjusted for hospital.

†OR adjusted for age.

‡OR adjusted for gender.

BMI, body mass index; BTS, British Thoracic Society; IDDM, insulin-dependent diabetes mellitus; NIDDM, non-insulin-dependent diabetes mellitus.

impact on patient morbidity and overall well-being. The influence of comorbidity on quality of life and functional status has previously been studied and shown to have a negative impact on quality-of-life scores.¹⁹ Additionally, subjects in the corticosteroid-dependent group were less likely to be in full-time employment and more likely to report impairment at work causing a reduction in working hours or complete inability to work. All of these constitute indirect costs of SA with a further link to daily OCS use and are likely to account for a substantial amount of overall costs for this cohort.

The presence of comorbidity places a substantial burden on individuals and healthcare systems, irrespective of the underlying cause. These data have shown that most subjects with SA have multiple conditions which need to be managed and prevented where possible. Previous studies have shown that comorbid conditions and, in particular, asthma-related comorbidity, is associated with increased healthcare use and with a negative effect on health status, functional impairment and quality of life.^{19–21 27 28} Taken collectively, these effects have major implications for patients with SA and also for specialists aiming to provide effective management of these patients, as well as placing a substantial burden on healthcare systems. It is worth mentioning that the mean age of subjects from both

the BTS Registry and OPCR is early to mid-50s and with such a heavy burden of comorbidity identified, the long-term implications of costs in this population would be considerable. Even at the age of 50, patients may be on a path towards a long-term burden of multiple chronic diseases with substantial healthcare and personal costs.

Our analysis has a number of potential limitations. Owing to the cross-sectional nature of the datasets, the causality of effects is difficult to ascertain. These conditions might have preceded OCS use. However, the difference between subjects with SA receiving maintenance OCS and those receiving frequent courses of OCS for long periods does suggest a causal relationship between regular (daily) OCS use and the additional morbidity. Additionally, supporting this argument, the adverse effects we explored are all recognised as being associated with corticosteroid exposure. We were interested in investigating the influence of the dose and duration of treatment on the occurrence of adverse effects in a population exposed to oral corticosteroids. However, owing to the nature of the data from both the BTS Registry and OPCR, it is difficult to identify the date at which significant systemic steroid exposure started and many of these subjects might have been exposed to systemic steroids for decades from a time when prescription records are not available

Table 5 Prevalence rates: OPCRD compared with the BTS Registry

Morbidity	OPCRD Severe asthma n=808 (%)	95% CI	BTS (all subjects) n=770 (%)	95% CI
Type II diabetes	10	(8 to 12)	10	(8 to 13)
Obesity (BMI >30)	42	(39 to 45)	50	(46 to 53)
Osteopenia	10	(8 to 12)	35	(31 to 40)
Osteoporosis	16	(13 to 18)	17	(14 to 21)
Fracture	5	(4 to 7)	2	(1 to 3)
Dyspeptic disorders	65	(61 to 68)	57	(54 to 61)
Glaucoma	4	(3 to 6)	2	(1 to 3)
Cataract	9	(7 to 11)	3	(2 to 5)
Cardiovascular disease	10	(8 to 12)	7	(5 to 9)
Hypertension	34	(31 to 38)	19	(16 to 22)
Psychiatric disorders	38	(35 to 42)	22	(19 to 25)
Hypercholesterolaemia	15	(13 to 18)	13	(11 to 16)
Sleep disorder	4	(3 to 6)	11	(9 to 14)

BMI, body mass index; BTS, British Thoracic Society; OPCRD, Optimum Patient Care Research Database.

or accurate. It is also challenging to identify precisely the daily dose of OCS or duration of treatment and whether a subject has taken intermittent frequent steroids or received regular maintenance treatment with less frequent episodic boosts of treatment. We believe that to perform this type of analysis would require a prospective cohort of patients with refractory asthma with data before the onset of OCS exposure. However, given that the definition of severe refractory asthma is predicated on the requirement for high-dose steroid treatment, we believe that identifying such a cohort before initiation of steroids is virtually impossible.

We did not specifically exclude any systemic corticosteroid exposure in the OPCRD cohort with mild/moderate asthma as we wished this group to reflect usual steroid exposure in this group. They had a median OCS dose of 250 mg exposure (which is broadly equivalent to a single rescue course of steroids over a 2-year period). As with all database studies, problems such as coding errors should be considered, and data such as socioeconomic markers were not available. Additionally, there may be a degree of confounding by severity with higher comorbidity detection in patients with SA who frequently attend their general practitioner with asthma. We believe that some of these effects were minimised by 'validating' prevalence rates across the two different datasets, and the similar prevalence rates of type II diabetes, obesity, osteoporosis, dyspeptic disorders and hypercholesterolaemia across the two datasets supports our analysis that these are accurate estimates in this population.

CONCLUSION

In conclusion, we have identified cross-sectional prevalence rates for adverse effects which are commonly related to systemic corticosteroid use. These rates are greater in subjects with SA who progress to maintenance (daily) corticosteroids than in subjects with SA who have frequent rescue courses and in subjects with mild/moderate asthma.

The most important clinical implication of these findings, given the frequency of these morbidities and the potential effect on patients' health and overall quality of life, is that detailed screening programmes should be in place for patients with SA receiving regular systemic corticosteroids. The need for better targeting of corticosteroid therapy in asthma using objective biomarker-based strategies and the urgent delivery of new treatments which will both reduce exposure to OCS and the overall

burden of disease are critical. Ideally, new treatments should be introduced before the introduction of systemic corticosteroids as maintenance treatment to prevent the adverse effects discussed.

Author affiliations

- ¹Centre for Infection and Immunity, Queen's University of Belfast, Belfast, UK
- ²Centre for Public Health, Queen's University of Belfast, Belfast, UK
- ³Royal Brompton Hospital, London, UK
- ⁴MAHSC, The University of Manchester & UHSM, Manchester, UK
- ⁵Severe and Brittle Asthma Unit, Birmingham Heartlands Hospital, Birmingham, UK
- ⁶Department of Respiratory Medicine, Royal Infirmary, Glasgow, UK
- ⁷Division of Immunology, Infection and Inflammation, Department of Respiratory Medicine, University of Glasgow and Gartnavel General, Glasgow, UK
- ⁸Academic Primary Care, University of Aberdeen, Aberdeen, UK
- ⁹Department of Infection, Inflammation and Immunity, Institute for Lung Health, University of Leicester, Leicester, UK

Acknowledgements We are grateful to the data input staff and medical and nursing staff at the BTS Registry Difficult Asthma Centres. We thank the Respiratory Effectiveness Group for supporting this project.

Contributors Data were acquired by all authors. The study was conceived and designed by JS, CCP, DP and LGH. JS, CCP and LGH were responsible for analysis and interpretation. JS and LGH drafted the manuscript. All authors approved and edited the final version of the manuscript.

Funding This work was supported by unrestricted research grants from Glaxo Smith Kline and F Hoffmann-La Roche Ltd and was performed in collaboration with the Respiratory Effectiveness Group.

Competing interests AM-G: grants and personal fees from Glaxo SmithKline; grants, personal fees and non-financial support from Novartis; personal fees from Napp; grants and personal fees from Roche; grants, personal fees and non-financial support from Boehringer Ingelheim; personal fees from AstraZeneca; personal fees from Chiesi; personal fees from Amgen; personal fees from Johnson & Johnson, outside the submitted work. RMN: personal fees from lecture fees and advisory boards, outside the submitted work. AHM: personal fees from Napp; personal fees from AstraZeneca; personal fees from Aerocrine; personal fees from Glaxo SmithKline; grants, personal fees and other from Novartis; personal fees and other from Boehringer; grants and personal fees from Roche, outside the submitted work. RC: grants from Novartis; grants from Roche, Glaxo SmithKline, AstraZeneca, Janssen, Novartis; personal fees from Novartis advisory board meeting; non-financial support from Novartis, Teva and Boehringer Ingelheim, outside the submitted work. DP: other funding from Aerocrine, Almirall, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Meda, Mundipharma, Napp, Novartis and Teva; other from Almirall, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Meda, Mundipharma, Napp, Novartis, Pfizer and Teva; grants from the UK National Health Service, British Lung Foundation, Aerocrine, AstraZeneca, Boehringer Ingelheim, Chiesi, Eli Lilly, GlaxoSmithKline, Meda, Merck, Mundipharma, Novartis, Orion, Pfizer, Respiratory Effectiveness Group, Takeda, Teva and Zentiva; other from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Meda, Merck, Mundipharma, Novartis, Pfizer, SkyePharma, Takeda and Teva; other

from Mundipharma and Teva, other from Aerocrine, Boehringer Ingelheim, Mundipharma, Napp, Novartis and Teva; other from Almirall, Chiesi, Teva and Zentiva; other from Aerocrine, AKL Ltd, Almirall, Boehringer Ingelheim, Chiesi, Meda, Mundipharma, Napp, Novartis, Orion, Takeda, Teva, Zentiva, outside the submitted work; In addition, DP has a patent AKL Ltd pending and has shares in AKL Ltd, which produces phytopharmaceutical agents. He owns 80% of Research in Real Life Ltd and its subsidiary social enterprise Optimum Patient Care. CEB: grants and consultancy fees from GSK, AZ/MedImmune, Novartis, Chiesi, Roche/Genentech and BI. LGH: research grants from Glaxo Smith Kline and from Hoffmann la Roche, during the conduct of the study. He has received grant funding from MedImmune, Novartis UK, Roche/Genentech Inc, Astra Zeneca and Glaxo Smith Kline, and has taken part in advisory boards and given lectures at meetings supported by Glaxo Smith Kline, Respivert, Merck Sharpe and Dohme, Nycomed, Boehringer Ingelheim, Novartis and Astra Zeneca. He has received support funding to attend international respiratory meetings (Astra Zeneca, Chiesi, Novartis, Boehringer Ingelheim and Glaxo Smith Kline) and has taken part in asthma clinical trials (GSK, Schering Pough, Synairgen and Roche/Genentech) for which his institution was remunerated. He is academic lead for the MRC Stratified Medicine UK Consortium in Severe Asthma which involves industrial partnerships with Amgen, Johnson & Johnson, Genentech/Roche, Astra Zeneca/MedImmune, Aerocrine and Vitalograph.

Ethics approval Ethical approval for the BTS Registry was obtained from the Office for Research Ethics Committees Northern Ireland (ORECNI) (reference number 10/NIRO2/37). OPCR is approved by the Trent Multi-Centre Research Ethics Committee for use within clinical research. The study protocol was approved by the Anonymised Data Ethics Protocols and Transparency Committee (ADEPT).

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

- Chung KF, Wenzel SE, Brozek JL, *et al.* International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. *Eur Respir J* 2014;43:343–73.
- Poetker DM, Reh DD. A comprehensive review of the adverse effects of systemic corticosteroids. *Otolaryngol Clin North Am* 2010;43:753–68.
- Manson SC, Brown RE, Cerulli A, *et al.* The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use. *Respir Med* 2009;103:975–94.
- Sarnes E, Crofford L, Watson M, *et al.* Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review. *Clin Ther* 2011;33:1413–32.
- Fardet L, Flahault A, Kettaneh A, *et al.* Corticosteroid-induced clinical adverse events: frequency, risk factors and patient's opinion. *Br J Dermatol* 2007;157:142–8.
- Shah M, Chaudhari S, McLaughlin TP, *et al.* Cumulative burden of oral corticosteroid adverse effects and the economic implications of corticosteroid use in patients with systemic lupus erythematosus. *Clin Ther* 2013;35:486–97.
- Ethgen O, de Lemos Esteves F, Bruyere O, *et al.* What do we know about the safety of corticosteroids in rheumatoid arthritis? *Curr Med Res Opin* 2013;29:1147–60.
- Walsh LJ, Wong CA, Osborne J, *et al.* Adverse effects of oral corticosteroids in relation to dose in patients with lung disease. *Thorax* 2001;56:279–84.
- Smyllie H, Connolly C. Incidence of serious complications of corticosteroid therapy in respiratory disease: a retrospective survey of patients in the Brompton Hospital. *Thorax* 1968;23:571–81.
- Rees HA, Williams DA. Long-term steroid therapy in chronic intractable asthma. A study of 317 adult asthmatics on continuous steroid therapy for an average period of 2 1/2 years. *BMJ* 1962;1:1575–9.
- Lieberman P, Patterson R, Kunske R. Complications of long-term steroid therapy for asthma. *J Allergy Clin Immunol* 1972;49:329–36.
- Pearson RB, Baylis J, Smellie H. Treatment of chronic asthma with prednisolone and the newer steroids. *BMJ* 1961;1:315.
- Fitzsimons R, Grammer LC, Halwig JM, *et al.* Prevalence of adverse effects in corticosteroid dependent asthmatics. *N Engl Reg Allergy Proc* 1988;9:157–62.
- Zazzali JL, Broder M, Chang E. Oral corticosteroid use increases the risk of glucocorticoid-related adverse events in asthmatics. *J Allergy Clin Immunol* 2012;129:AB74.
- Zazzali JL, Broder MS, Omachi MD, *et al.* Risk of corticosteroid-related adverse events in asthma patients with high oral corticosteroid use. *Allergy Asthma Proc* 2015;36:268–74.
- Price D, Ryan D, Burden A, *et al.* Using fractional exhaled nitric oxide (FeNO) to diagnose steroid-responsive disease and guide asthma management in routine care. *Clin Transl Allergy* 2013;3:37.
- Heaney LG, Brightling CE, Menzies-Gow A, *et al.*, British Thoracic Society Difficult Asthma Network. Refractory asthma in the UK: cross-sectional findings from a UK multicentre registry. *Thorax* 2010;65:787–94.
- Stappuhn H, Langen U, Scheidt-Nave C, *et al.* Major comorbid conditions in asthma and association with asthma-related hospitalizations and emergency department admissions in adults: results from the German national health telephone interview survey (GEDA) 2010. *BMC Pulm Med* 2013;13:46.
- Adams RJ, Wilson DH, Taylor AW, *et al.* Coexistent chronic conditions and asthma quality of life: a population-based study. *Chest* 2006;129:285–91.
- Zhang T, Carleton BC, Prosser RJ, *et al.* The added burden of comorbidity in patients with asthma. *J Asthma* 2009;46:1021–6.
- Gershon AS, Wang C, Guan J, *et al.* Burden of comorbidity in individuals with asthma. *Thorax* 2010;65:612–8.
- Karlstad Ø, Nafstad P, Tverdal A, *et al.* Comorbidities in an asthma population 8–29 years old: a study from the Norwegian Prescription Database. *Pharmacoepidemiol Drug Saf* 2012;21:1045–52.
- Park J, Kim T, Joo H, *et al.* Diseases concomitant with asthma in middle-aged and elderly subjects in Korea: a population-based study. *Allergy Asthma Immunol Res* 2013;5:16–25.
- Fardet L, Kassab A, Cabane J, *et al.* Corticosteroid-induced adverse events in adults. *Drug Saf* 2007;30:861–81.
- British Thoracic Society/Scottish Intercollegiate Guidelines Network. British Guideline on the Management of Asthma—A National Clinical Guideline. Revised January 2012. 2012. <http://www.brit-thoracic.org.uk/Portals/0/Guidelines/AsthmaGuidelines/sign101%20Jan%202012.pdf>
- Global Initiative for Asthma (GINA). *Global Strategy for Asthma Management and Prevention*. 2014. <http://www.ginasthma.org/>
- Stappuhn H, Langen U, Keil T, *et al.* Chronic disease co-morbidity of asthma and unscheduled asthma care among adults: results of the national telephone health interview survey German Health Update (GEDA) 2009 and 2010. *Prim Care Respir J* 2014;23:22–9.
- Adams RJ, Wilson DH, Taylor AW, *et al.* Psychological factors and asthma quality of life: a population based study. *Thorax* 2004;59:930–5.

Online Data Supplement

Comorbidity in Severe Asthma requiring systemic corticosteroid therapy - Cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry

Joan Sweeney¹; Chris C Patterson², Andrew Menzies-Gow³, Rob M Niven⁴, Adel H Mansur⁵, Christine Bucknall⁶, Rekha Chaudhuri⁷, David Price⁸, Chris E Brightling⁹, Liam G Heaney¹ on behalf of the British Thoracic Society Difficult Asthma Network

¹Centre for Infection and Immunity, Queen's University of Belfast, UK. ²Centre for Public Health, Queen's University of Belfast, UK, ³Royal Brompton Hospital, London, UK, ⁴MAHSC, The University of Manchester & UHSM, Manchester, UK, ⁵Severe and Brittle Asthma Unit, Birmingham Heartlands Hospital. ⁶Department of Respiratory Medicine, Royal Infirmary, Glasgow, UK, ⁷Department of Respiratory Medicine, Division of Immunology, Infection and Inflammation, University of Glasgow and Gartnavel General, Glasgow, UK, ⁸Academic Primary Care, University of Aberdeen, UK, ⁹Department of Infection, Inflammation and Immunity, Institute for Lung Health, University of Leicester, UK.

Methods

The British Thoracic Society (BTS) Difficult Asthma Registry

In 2007, the BTS Research Committee, in conjunction with physicians with a specialist interest in difficult asthma, established a National Registry for dedicated UK Difficult Asthma services. The aims of the group were to define clinical phenotypes in subjects with well-characterized severe asthma (SA), to facilitate research into the assessment and clinical management of difficult asthma, to develop and increase access to dedicated difficult asthma service and to standardise clinical care in specialist clinical supra-regional clinical centres (1).

There are currently eight dedicated Specialist Difficult Asthma Services submitting data to the UK Registry - Royal Brompton Hospital, London; Glenfield Hospital, Leicester; University Hospital of South Manchester; Birmingham Heartlands Hospital; Gartnavel Hospital, Glasgow; Stobhill Hospital, Glasgow, Southampton General Hospital and Belfast City Hospital. The Registry is hosted online by Dendrite Clinical Systems Ltd and collects password-protected, anonymous data after fully informed written consent has been obtained from patients. The registry records patient demographics including gender, age at diagnosis, occupation and BMI as well as disease characteristics such as asthma medication, exacerbations, and pulmonary function. Patients at all centres undergo a standardised multidisciplinary, systematic assessment of their asthma. All Registry centres follow protocols whereby patients have multiple investigations, including a thorough medical history and examination, pulmonary function tests, allergy assessment (skin-prick testing and/or radioallergosorbent test), blood tests (incorporating serum eosinophil count and


IgE), bone densitometry and complete health related quality of life and asthma control questionnaires (Asthma Control Questionnaire (ACQ), Asthma Quality of Life Questionnaire (AQLQ), EuroQol EQ-5D-Generic quality of life questionnaire, Hospital, Anxiety and Depression Scale (HAD)). Epworth Sleepiness Scale is also completed by patients and overnight oximetry/polysomnography performed if indicated. All Registry data including objective measures as listed above were examined for analysis.

The Optimum Patient Care Research Database

The OPCR is a large, longitudinal, primary care database offering anonymised research quality data with a focus on respiratory disease. It contains all point of care records for respiratory patients including comorbid disease information and prescriptions issued at time of healthcare contact. OPCR currently holds anonymised data on approximately 700,000 patients with asthma. The distribution of participating practices across the UK is shown in Figure E1. For the purposes of statistical analysis, geographical areas of practices were aggregated into six regions as follows.

Region	Postcode Areas
London	CR, E, EN, HA, IG, KT, N, NW, RM, SM, TW, UB, W
South	BA, BS, CT, GL, GU, HP, ME, MK, OX, PL, RG, RH, SL, SN, TA
East	CB, CO, IP, LN, LU, NR, PE, SS
Midlands	B, CV, DE, LE, NG, NN, ST, WS, WV
North	BD, CA, CH, CW, DH, FY, HD, HG, HX, L, LA, LS, M, NE, OL, SR, TS, WA, WN, YO
Outside England or missing	AB, BT, DD, EH, G, ML, PH, SY

Figure E1 **OPCRD practice distribution**



OPCRD Cohort Definition

Severe Asthma population

All subjects must have had a Read Code diagnosis of asthma in the GP record and have received prescriptions for Step 5 GINA asthma treatment during a 2-year qualification period defined as continuous or frequent use of OCS and high dose inhaled corticosteroid maintained at 2000mcg BDP equivalent/day (2). It is not possible to identify maintenance or daily OCS use from GP prescription records so in order to capture subjects receiving continuous or with frequent use of OCS, an inclusion criterion of ≥ 4 prescriptions for

systemic corticosteroids in each of the two study years was specified for this population. A sub-group of SA subjects who received maintenance systemic corticosteroids quantified by ≥ 6 OCS prescriptions in both years of the study was further evaluated in a sensitivity analysis.

Mild/moderate asthma population

The asthma population within OPCRCD are coded according to their asthma therapy and corresponding GINA steps of asthma management. To be included in the mild/moderate asthma population, all subjects must have had a Read Code diagnosis of asthma and have received prescriptions for Step 2-3 GINA (Read Code for GINA Step 2 or Step 3) treatment during the 2-year qualifying period defined as 'regular preventer therapy with add on asthma therapy'. This included inhaled corticosteroid therapy of 200-800mcg BDP equivalent dose/day with or without long-acting beta-agonist therapy or if control was still inadequate other asthma therapies such as leukotriene receptor antagonist or SR theophylline may have been prescribed (2). This mild/moderate population may have received none or rescue courses of OCS only during the 2 year qualifying period.

Control population

To be considered part of the 'non-asthmatic control' population, subjects must not have had a Read Code diagnosis of asthma but must have had a Read Code diagnosis of rhinitis or received therapy to treat rhinitis (i.e. drugs used in nasal allergy). As the OPCRCD is a respiratory database, this population was chosen as the 'non-asthmatic controls' as they did

not have any exposure to OCS or have any other condition that warranted OCS use and they did not have a Read Code/ diagnosis for asthma.

Matching criteria

Matching criteria was based on subjects:

- Age
- Gender
- Year of birth


Exclusion criteria

For all study subjects and to minimize the risk of confounding by non-asthmatic systemic steroid exposure, subjects with any of the following conditions (for which systemic corticosteroid treatment could be prescribed) were excluded from the study population:


- Crohn's disease
- Ulcerative colitis
- Autoimmune diseases – autoimmune hepatitis
- Joint and muscle diseases – rheumatoid arthritis, polymyalgia rheumatica
- Chronic respiratory conditions other than asthma, i.e. Chronic Obstructive Pulmonary Disease (COPD); bronchiectasis; cystic fibrosis; interstitial pulmonary fibrosis; tuberculosis.

Figure E2 presents flowcharts for OPCR data extraction and cohort matching.


Figure E2 OPCRD data extraction and cohort matching flowcharts for severe (refractory) asthma and controls



Matching of well controlled asthma patients to severe (refractory) asthma patients



Matching of non-asthma patients to severe (refractory) asthma patients




Study period

Eligibility for the cross-sectional analysis was evaluated over a 2-year qualifying period using the previously-defined inclusion/exclusion criteria. This was the latest 2-year period within the OPCRDR which at time of protocol design was 1 April 2011– 30 March 2013. In OPCRDR the latest date of download from some practices was prior to 1 April 2011 or similarly, the latest download may have taken place after 30 March 2013. In those circumstances, the date of the 2-year qualifying period differed from that stipulated in the protocol.

Figure E3 represents the study period for the OPCRDR analysis.

Figure E3 Schematic for definition of study period.



Morbidity evaluations OPCRDR

The most commonly reported adverse effects of OCS were evaluated (Table E1) (3-16). Read Codes are a coded thesaurus of clinical terms and have been in use in the NHS since 1985.

They are a basic means by which clinicians record patient findings and procedures across health and social care IT systems and are the clinical classification system currently used in primary care in the UK. OPCRD currently uses Version 2 Read Codes and all relevant coding was extracted from the NHS Read Code Browser and codes relating to the adverse effects listed below were then extracted from the OPCRD 'clinical' file for analysis. Rates are reported for each cohort and the rates in SA subjects are compared with the rates in mild/moderate asthma and non-asthmatic controls.

Table E1 Adverse effects of OCS use

Morbidity/Adverse Effect
Osteoporosis
Fracture
Diabetes
Hypertension
Ophthalmic effects – cataracts, glaucoma
Dyspeptic disorders – peptic ulcer disease
Psychiatric events – anxiety, depression, agitation
Infections
Sleep disturbances – insomnia
Dyslipidaemia
Weight gain
Skin conditions – bruising, thinning, striae, skin atrophy, acne
Muscle weakness/myopathy
Cardiovascular conditions – MI, heart failure
Oral candidiasis
Hyperglycaemia
Adrenal suppression/insufficiency
Osteonecrosis
Cushingoid changes – moon facies, abdominal obesity

Study size

The power of this study to detect excesses of steroid induced morbidity depends on the size of the groups, the frequency of the morbidity in the comparison group (mild/moderate asthmatic population or non-asthmatic population) and the magnitude of the excess rate expressed in terms of the relative risk, the ratio of the morbidity rates in the severe asthma and control groups. Table E2 shows the power of the main study of 800 asthma subjects on maintenance OCS and of the sub-group analysis of 450 receiving ≥ 6 OCS in each qualifying year to detect various relative risks depending on the prevalence of the morbidity.

Table E.2 Retrospective power assessment of a study of 800/450 asthma subjects on maintenance OCS to detect a given increase in risk as statistically significant ($P < 0.05$) assuming a comparison group 5-times the size.

Prevalence of morbidity in comparison group	Power of study of 800 patients (main analysis)				
	Relative risk				
	x1.25	x1.5	x2.0	x2.5	x3.0
1%	8%†	22%	58%	84%	100%
2%	13%	39%	86%	99%	100%
3%	19%	54%	96%	100%	100%
4%	24%	66%	99%	100%	100%
5%	29%	76%	100%	100%	100%
10%	53%	97%	100%	100%	100%
15%	73%	100%	100%	100%	100%
20%	68%	100%	100%	100%	100%
25%	87%	100%	100%	100%	100%
30%	100%	100%	100%	100%	100%

† Stata sample size and power calculation command: `sampsi 0.0125 0.01, n1(800) r(5)`

Prevalence of morbidity in comparison group	Power of study of 450 patients (sub-group analysis)				
	Relative risk				
	x1.25	x1.5	x2.0	x2.5	x3.0
1%	5%†	13%	38%	62%	84%
2%	9%	24%	64%	89%	97%
3%	12%	34%	80%	97%	100%
4%	15%	44%	90%	99%	100%
5%	18%	52%	95%	100%	100%
10%	33%	83%	100%	100%	100%
15%	49%	96%	100%	100%	100%
20%	63%	99%	100%	100%	100%
25%	76%	100%	100%	100%	100%
30%	86%	100%	100%	100%	100%

† Stata sample size and power calculation command: `sampsi 0.0125 0.01, n1(450) r(5)`

Statistical analysis

The conditional logistic regression model (17) was employed for statistical analysis to take account of the matching of severe asthma cases with well-controlled asthma controls and rhinitis (non-asthma) controls.

Suppose that the i^{th} of I matched groups contains one case and M_i matched controls.

Denote by $\mathbf{x}_{i0} = (\mathbf{x}_{i01}, \dots, \mathbf{x}_{i0K})$ the \mathbf{K} -vector of covariates ($\mathbf{k}=1, \dots, \mathbf{K}$) for case i ($i=1, \dots, I$), and denote by $\mathbf{x}_{ij} = (\mathbf{x}_{ij1}, \dots, \mathbf{x}_{ijK})$ the corresponding vector for the j th control ($j=1, \dots, M_i$). The conditional likelihood may be obtained as

$$\prod_{i=1}^I \frac{\exp(\sum_{k=1}^K \beta_k x_{i0k})}{\sum_{j=0}^{M_i} \exp(\sum_{k=1}^K \beta_k x_{ijk})} = \prod_{i=1}^I \frac{1}{1 + \sum_{j=1}^{M_i} \exp\{\sum_{k=1}^K \beta_k (x_{ijk} - x_{i0k})\}}$$

where β_k represents the regression parameter for covariate \mathbf{x}_k ($\mathbf{k}=1, \dots, \mathbf{K}$).

This likelihood can be maximised to obtain estimates \mathbf{b}_k of β_k together with their standard errors $SE(\mathbf{b}_k)$ ($\mathbf{k}=1, \dots, \mathbf{K}$). These estimates may be antilogged to provide odds ratios (OR), $\exp(\mathbf{b}_k)$, and 95% confidence limits (CI), $\exp(\mathbf{b}_k \pm 1.96 SE(\mathbf{b}_k))$ ($\mathbf{k}=1, \dots, \mathbf{K}$).

The covariates status (coded as case=1, control=0) and geographical region (coded as a series of dummy variables) were included in all analyses. Sample STATA commands for each analysis, with the adverse event non-insulin dependent diabetes (NIDDM), are given below,

xi:clogit NIDDM status i.region, group(MATCH_WELLCNTRL) or
xi:clogit NIDDM status i.region, group(MATCH_RHINITIS) or

where MATCH_WELLCNTRL identifies the matched groups of severe asthma and well-controlled asthma controls

and MATCH_RHINITIS identifies the matched groups of severe asthma and rhinitis (non-asthmatic) controls.

Results

Sub-group analysis of severe asthma subjects receiving ≥ 6 OCS

Minor change was noted in prevalence rates in this analysis (Table E3). The odds of osteopenia in SA compared to non-asthma controls increased 2-fold from the original analysis to OR of 8.72 (95% CI 5.15-14.75) from OR of 6.68 (4.28-10.43). Prevalence rates and OR for fractures in refractory asthma compared to controls was no longer statistically significant. Similarly, the rates and OR of cardiovascular disease in SA compared to mild/moderate asthma failed to reach statistical significance.

Table E3 Sub-group analysis of severe asthma subjects receiving ≥ 6 OCS in each qualifying year OPCR

Morbidity	Severe asthma (%) n=465	Mild/moderate asthma (%) n=2280	OR (95% CI)	p-value	Non-asthma controls (%) n=1375	OR (95%CI)	p-value
Type II diabetes	53(11%)	161(7%)	1.69(1.22-2.35)	0.001	89(7%)	1.86(1.30-2.66)	0.001
Obesity (BMI >30)	194(42%)	808(35%)	1.30(1.06-1.60)	0.010	328(24%)	2.29(1.83-2.85)	p<0.001
Osteopenia	53(11%)	55(2%)	5.21(3.52-7.69)	p<0.001	20(2%)	8.72(5.15-14.75)	p<0.001
Osteoporosis	86(19%)	99(4%)	5(3.68-7.69)	p<0.001	43(3%)	7.03(4.79-10.31)	p<0.001
Fracture	22(5%)	79(4%)	1.38(0.85-2.24)	0.19	50(4%)	1.32(0.79-2.20)	0.29
Dyspeptic disorders	318(68%)	790(35%)	4.08(3.30-5.05)	p<0.001	337(25%)	6.66(5.29-8.39)	p<0.001
Glaucoma	23(5%)	88(4%)	1.30(0.81-2.07)	0.28	45(3%)	1.54(0.92-2.57)	0.10
Cataract	51(11%)	127(6%)	2.09(1.48-2.94)	p<0.001	59(4%)	2.75(1.86-4.06)	p<0.001
Cardiovascular disease	48(10%)	176(8%)	1.38(0.98-1.93)	0.06	97(7%)	1.52(1.06-2.18)	0.024
Hypertension	163(35%)	680(30%)	1.27(1.03-1.57)	0.026	350(26%)	1.58(1.26-1.98)	p<0.001
Psychiatric conditions/ Anxiety/depression	173(37%)	707(31%)	1.32(1.07-1.62)	0.009	352(26%)	1.72(1.38-2.15)	p<0.001
Hypercholesterolemia	75(16%)	338(15%)	1.10(0.84-1.45)	0.47	148(11%)	1.59(1.18-2.15)	0.002
Sleep disorder	19(4%)	56(3%)	1.69(1.00-2.87)	0.049	22(2%)	2.62(1.41-4.89)	0.002
Chronic kidney disease	74(16%)	202(9%)	1.95(1.46-2.60)	p<0.001	93(7%)	2.61(1.88-3.61)	p<0.001

References

- (1) Heaney LG, Brightling CE, Menzies-Gow A, Stevenson M, Niven RM, British Thoracic Society Difficult Asthma Network. Refractory asthma in the UK: cross-sectional findings from a UK multicentre registry. *Thorax* 2010 Sep;65(9):787-794.
- (2) Global Initiative for Asthma (GINA). *Global Strategy for Asthma Management and Prevention* 2014. Available from: <http://www.ginasthma.org/>.
- (3) Sarnes E, Crofford L, Watson M, Dennis G, Kan H, Bass D. Incidence and US Costs of Corticosteroid-Associated Adverse Events: A Systematic Literature Review. *Clin Ther* 2011 10;33(10):1413-1432.
- (4) Manson SC, Brown RE, Cerulli A, Vidaurre CF. The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use. *Respir Med* 2009 7;103(7):975-994.
- (5) Walsh LJ, Wong CA, Osborne J, Cooper S, Lewis SA, Pringle M, et al. Adverse effects of oral corticosteroids in relation to dose in patients with lung disease. *Thorax* 2001;56(4):279-284.
- (6) Smyllie H, Connolly C. Incidence of serious complications of corticosteroid therapy in respiratory disease A retrospective survey of patients in the Brompton Hospital. *Thorax* 1968;23(6):571-581.
- (7) Rees, H.A. & Williams, D.A. Long-term steroid therapy in chronic intractable asthma. A study of 317 adult asthmatics on continuous steroid therapy for an average period of 2 1/2 years. *Br Med J* 1962;1(5292):1575-1579.
- (8) Lieberman P, Patterson R, Kunske R. Complications of long-term steroid therapy for asthma. *J Allergy Clin Immunol* 1972;49(6):329-336.
- (9) Pearson RB, Baylis J, Smellie H. Treatment of chronic asthma with prednisolone and the newer steroids. *Br Med J* 1961;1(5222):315.
- (10) Fardet L, Flahault A, Kettaneh A, Tiev K, Génereau T, Tolédano C, et al. Corticosteroid-induced clinical adverse events: frequency, risk factors and patient's opinion. *Br J Dermatol* 2007;157(1):142-148.
- (11) Zazzali JL, Broder M, Chang E. Oral Corticosteroid Use Increases the Risk of Glucocorticoid-related Adverse Events in Asthmatics. *J Allergy Clin Immunol* 2012 02/01;129(2):AB74.
- (12) Fitzsimons R, Grammer LC, Halwig JM, Aksamit T, Patterson R. Prevalence of adverse effects in corticosteroid dependent asthmatics. *N Engl Reg Allergy Proc* 1988;9(2):157-162.
- (13) Poetker DM, Reh DD. A comprehensive review of the adverse effects of systemic corticosteroids. *Otolaryngol Clin North Am* 2010 08;43(4):753-768.
- (14) Shah M, Chaudhari S, McLaughlin TP, Kan HJ, Bechtel B, Dennis GJ, et al. Cumulative Burden of Oral Corticosteroid Adverse Effects and the Economic Implications of Corticosteroid Use in Patients With Systemic Lupus Erythematosus. *Clin Ther* 2013;35(4):486-497.
- (15) Ethgen O, de Lemos Esteves F, Bruyere O, Reginster J. What do we know about the safety of corticosteroids in rheumatoid arthritis? *Current Medical Research & Opinion* 2013;29(9):1147-1160.
- (16) Zazzali JL., Broder MS., Omachi MD., Chang E., Sun GH., Raimundo K. Risk of corticosteroid-related adverse events in asthma patients with high oral corticosteroid use. *Allergy Asthma Proc.* 2015 Jul;36(4):268-74. doi: 10.2500/aap.2015.36.3863
- (17) Breslow NE, Day NE: *Statistical methods in cancer research: Volume I - The design and analysis of case control studies.* IARC Scientific Publications No. 32, Lyon, 1980.